Accéder au contenu principal

hfpef-diva

an ERA4Health research consortium

HFpEF-DIVA

Diverging HFpEF Phenotypes : patient-tailoreD targeting of anti-Inflammatory pathways to limit Ventricular and Atrial remodelling

 

Introduction & Scope

Heart Failure with preserved Ejection Fraction (HFpEF) is associated with multiple comorbidities such as atrial fibrillation (AF). New treatments are urgently needed to reduce progression and severity of these diseases. Low-grade inflammation, triggered by common risk factors, e.g. metabolic stress, may drive disease-progression in both HFpEF and AF.

We hypothesize that targeting pro-inflammatory pathways, including interleukin (IL)-6, may reduce disease development.

The ultimate goal of HFpEF-DIVA is to enable and direct Personalized Medicine to better treat individual patients by tailoring the therapy to their respective cardiovascular inflammatory profiles to limit HFpEF.

New review on the topic

We have recently reviewed the immune mechanisms and targets in HFpEF together with 3 of our early-stage researchers: Ellaline, Eline and Emily. Please check it out: 

Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets. Ellaline Cami, Eline Verghote, Emily Pecetto, Arantxa González, Ebba Brakenhielm, Elizabeth Av Jones, Vanessa Van Empel Curr Heart Fail Rep 2026 ;23(1):36. doi: 10.1007/s11897-026-00745-0

Video presentations

 English

 UK

   French

 France

 Spanish

 Spain

   Dutch

 Dutch

 German

 Germany

   Swedish

 Sweden

Italian

italy

Mandarin

mandarin
Our-early-stage-researcher